GLOBAL COST EFFECTIVE ANALYSIS OF APIXABAN VERSUS WARFARIN FOR THE PREVENTION OF STROKE AS A RESULT OF ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW

被引：0
|
作者：
Petrenchik, L. [1 ]
Hussain, N. [1 ]
Charles, P. [1 ]
Peprah, H. [1 ]
Loh, F. E. [1 ]
机构：
[1] Touro Coll Pharm, New York, NY USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.372
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV50
引用
收藏
页码：S61 / S61
页数：1
相关论文
共 50 条
  • [21] A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
    Pinyol C.
    Cepeda J.M.ª
    Roldan I.
    Roldan V.
    Jimenez S.
    Gonzalez P.
    Soto J.
    Cardiology and Therapy, 2016, 5 (2) : 171 - 186
  • [22] Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation
    Xiong, Qinmei
    Lau, Yee C.
    Lip, Gregory Y. H.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2015, 4 (04) : 367 - 376
  • [23] Apixaban versus Warfarin in Atrial Fibrillation REPLY
    Mega, Jessica L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (01): : 89 - 90
  • [24] Apixaban versus Warfarin in Patients with Atrial Fibrillation
    Granger, Christopher B.
    Alexander, John H.
    McMurray, John J. V.
    Lopes, Renato D.
    Hylek, Elaine M.
    Hanna, Michael
    Al-Khalidi, Hussein R.
    Ansell, Jack
    Atar, Dan
    Avezum, Alvaro
    Cecilia Bahit, M.
    Diaz, Rafael
    Easton, J. Donald
    Ezekowitz, Justin A.
    Flaker, Greg
    Garcia, David
    Geraldes, Margarida
    Gersh, Bernard J.
    Golitsyn, Sergey
    Goto, Shinya
    Hermosillo, Antonio G.
    Hohnloser, Stefan H.
    Horowitz, John
    Mohan, Puneet
    Jansky, Petr
    Lewis, Basil S.
    Luis Lopez-Sendon, Jose
    Pais, Prem
    Parkhomenko, Alexander
    Verheugt, Freek W. A.
    Zhu, Jun
    Wallentin, Lars
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (11): : 981 - 992
  • [25] Apixaban for the prevention of stroke in atrial fibrillation
    Littrell, Rachel
    Flaker, Greg
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (02) : 143 - 149
  • [26] Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
    Torbjørn Wisløff
    Gunhild Hagen
    Marianne Klemp
    PharmacoEconomics, 2014, 32 : 601 - 612
  • [27] Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
    Wisloff, Torbjorn
    Hagen, Gunhild
    Klemp, Marianne
    PHARMACOECONOMICS, 2014, 32 (06) : 601 - 612
  • [28] Dabigatran may be a cost-effective alternative to warfarin for stroke prevention in atrial fibrillation
    不详
    FORMULARY, 2011, 46 (02) : 39 - 39
  • [29] PREVENTION OF STROKE IN PATIENTS WITH ATRIAL FIBRILLATION: COST-UTILITY ANALYSIS OF RIVAROXABAN VERSUS WARFARIN IN SLOVAKIA
    Psenkova, M.
    Lukac, M.
    Mackovicova, S.
    Stachova, M.
    Bielik, J.
    Pietsch, G. A.
    Asukai, Y.
    Lloyd, A.
    Evers, T.
    VALUE IN HEALTH, 2012, 15 (07) : A375 - A375
  • [30] Cost-effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
    Pradelli, Lorenzo
    Calandriello, Mario
    Di Virgilio, Roberto
    Bellone, Marco
    Tubaro, Marco
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2014, 15 (04) : 101 - 112
12345